Cetuximab antibody | AbD19376_hIgG1

100% Secure


Human anti Cetuximab:HRP

Anti-cetuximab antibody is a non-neutralizing anti-idiotypic IgG1 antibody; it is ideal for bioanalytical assays for cetuximab and biosimilars. It does not inhibit the binding of cetuximab to EGFR; it is suitable as a detection antibody in PK bridging ELISA with HCA220 to measure total drug.

Human anti Cetuximab

Anti-cetuximab antibody is a non-neutralizing anti-idiotypic IgG1 antibody; it is ideal for bioanalytical assays for cetuximab and biosimilars. It does not inhibit the binding of cetuximab to EGFR; it is suitable as a detection antibody in PK bridging ELISA with HCA220 to measure total drug.

Product Type
Monoclonal Antibody
Clone
AbD19376_hIgG1
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
HCA228P E 0.1 mg
HCA228 E 0.1 mg
Human anti cetuximab, clone AbD19376_hIgG1, is a non-inhibitory anti-idiotypic antibody that binds to cetuximab. This antibody recognizes an epitope outside the cetuximab binding site and so does not inhibit the binding of the drug to its target. This epitope is shared with other chimeric antibodies that are highly homologous to cetuximab including infliximab but excluding rituximab.

Clone AbD19376_hIgG1 is a fully human antibody and may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) levels in patient sera. In the HRP-conjugated format, clone AbD19376_IgG1 is suitable as a detection antibody in pharmacokinetic (PK) assays to measure total cetuximab levels (free drug, partially bound and fully bound). Anti cetuximab antibody HCA220 is recommended as the capture antibody.

Cetuximab (brand name Erbitux®) is a chimeric monoclonal antibody drug (IgG1/kappa) approved for treatment of KRAS wild-type metastatic colorectal cancers and squamous cell carcinoma of the head and neck. This therapeutic antibody is directed against EGFR and inhibits tumor cell proliferation by blocking the interaction of epidermal growth factor (EGF) with its receptor.

View a summary of all anti cetuximab antibodies.

Product Details

Product Form
Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
Product Form
Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.01% Thiomersal
Preservative Stabilisers
0.01% Thiomersal
Immunogen
Chimeric monoclonal antibody
Affinity
The monovalent intrinsic affinity of this antibody was measured as KD=39 nM by real time, label-free molecular interaction analysis on immobilized cetuximab.
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
Antibody concentration 0.5 mg/ml

Storage Information

Storage
Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
12 months from date of despatch
Shelf Life
12 months from date of despatch

More Information

Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory
For research purposes only

Applications of Cetuximab antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
ELISA
This product may be used in a direct ELISA or as a detection antibody in a cetuximab bridging ELISA for PK assay development together with HCA220 as the capture reagent.
Protocol: PK bridging ELISA to measure total drug
ELISA
This product may be used in a direct ELISA or when conjugated to HRP, as a detection antibody in a cetuximab bridging ELISA for PK assay development together with HCA220 as the capture reagent.
Protocol: PK bridging ELISA to measure total drug

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Cetuximab HCA220 0.1 mg E
Human anti Cetuximab HCA221 0.1 mg E
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Cetuximab HCA220 0.1 mg E
Human anti Cetuximab HCA221 0.1 mg E
LYNX Rapid HRP Antibody Conjugation Kit LNK002P 3 Conjugations For 400µg Antibody CJ

Product Specific References

References for Cetuximab antibody

  1. Bose, M.E. et al. (2016) Simulated Respiratory Secretion for Use in the Development of Influenza Diagnostic Assays.
    PLoS One. 11 (11): e0166800.
  2. Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
    US Patent Application US20170315118A1

Further Reading

  1. Gomez, D. et al. (2013) Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier?
    Int J Surg. 11 (7): 507-13.